



Start Your Day with Innovation in Multiple Myeloma Care

Exclusive 2025 IMS Annual Meeting Industry Symposium

A Road Map for Integration of Treatment of Relapsed and Refractory Multiple Myeloma in the Community: Harnessing the Power of BCMA Bispecific Antibodies - A Blueprint for Academic and Community Collaboration

Join global leaders in multiple myeloma for a dynamic discussion on how BCMA bispecific antibodies (BsABs) are reshaping care for patients with relapsed and refractory multiple myeloma (RRMM). Discover how to integrate this off-the-shelf, T cell-engaging therapy into community-based practice.

DATE: Friday, September 19th, 2025
TIME: 8:00 am – 9:00 am (EDT)
LOCATION: Metro Toronto Convention Center
Hall FG (General Session Room)
255 Front St W, Toronto, ON M5V 2W6

LEARNING OBJECTIVES

At the end of this symposium, participants will be able to:

- Evaluate the efficacy and safety of off-the-shelf BCMA T cell-engaging immunotherapy, such as BCMA BsABs, in RRMM
- Implement step-up dosing for BCMA BsABs in the outpatient setting
- Share best practices on integrating BCMA BsABs within community practice and regional centers

Should you have any questions, please contact
Manon Clastrier via email at mclastrier@medplan.ca

CHAIR

Andrew Yee, MD

Assistant Professor of Medicine,
Harvard Medical School
Clinical Director,
Center for Multiple Myeloma,
Massachusetts General Hospital
Cancer Center
Boston, MA, US

SPEAKERS

Albert Oriol, MD, PhD

Head of the Clinical Research Unit,
Catalan Institute of Oncology and
Josep Carreras Institute,
Hospital Germans Trias i Pujol
Badalona, Spain

Janet MacEachern, MD

Medical Director,
Stem Cell Transplantation and
Cellular Therapy,
Grand River Regional Cancer
Center and Grand River Hospital
Kitchener, ON, Canada

Arlene A. Gayle, MD

Medical Director,
Stem Cell Transplant Program
Clinical Research Leader,
Advent Health
Orlando, FL, US



Start Your Day with Innovation in Multiple Myeloma Care

Exclusive 2025 IMS Annual Meeting Industry Symposium

A Road Map for Integration of Treatment of Relapsed and Refractory Multiple Myeloma in the Community: Harnessing the Power of BCMA Bispecific Antibodies
- A Blueprint for Academic and Community Collaboration

TIME	TOPIC	SPEAKER(S)
8:00 – 8:05 AM	Welcome and Introductions	Andrew Yee, MD
8:05 – 8:20 AM	Bringing Innovative Therapies to the Point of Care: BCMA BsAbs in Relapsed and Refractory Multiple Myeloma	Andrew Yee, MD
8:20 – 8:30 AM	Clinical Considerations on Safety When Using BCMA BsAbs	Albert Oriol, MD, PhD
8:30 – 8:40 AM	Perspectives on Community Use of BCMA BsAbs: Expanding Access to Novel Therapies	Arlene A. Gayle, MD Janet MacEachern, MD
8:40 – 8:50 AM	Panel Discussion: Community Use of BCMA BsAbs	All faculty
8:50 – 9:00 AM	Conclusion and Q&A	All faculty